Browse the search results

A mechanistic mathematical model informed by standard‐of‐care imaging and pathology predicts tumor responses to immunotherapy a priori on a per-patient basis.

Measuring individual differences in noxious-evoked baseline sensitivity in neonates can substantially reduce sample sizes required in neonatal analgesic trials.

An analysis of more than 3000 randomized controlled trials published in JAMA, the Lancet and NEJM has identified 396 medical reversals.

Prevaccination levels of transcriptional modules related to monocytes, dendritic cells, and other immune categories correlate with clinical malaria risk in RTS,S/AS01E-vaccinated African children, suggesting that certain monocyte subsets may inhibit RTS,S/AS01E-induced protective responses.

Pathogenic activating mutations in PIK3CA or NRAS were the most common genetic findings in a lymphatic malformation patient cohort and an N-of-1 trial of the PI3Kα inhibitor alpelisib in a patient with a PIK3CA mutation confirmed these findings are actionable.

Circulating immune cells reflect intra-tumoural immunity and can predict response to systemic therapy in head and neck cancer.

Results from the Reproducibility Project: Cancer Biology provide a picture of the rate of false positives in cancer preclinical research, but it is still not clear if research in this field is less reproducible than it should be.

Complete blood count data can increase the accuracy of the diagnosis of severe malaria in children in high transmission settings.

Treatment with a JAK inhibitor normalizes multiple biomarkers of autoinflammation and provides therapeutic benefit for diverse immune skin conditions in individuals with Down syndrome.